FDA Approves First Radioligand Equivalent, Curium’s Copycat of Novartis’ Lutathera

The FDA has granted approval for Curium’s lutetium Lu 177 dotatate injection, branded as Bexlutry, marking a significant milestone as the first radioligand equivalent in the industry. This approval follows Curium’s successful defense against patent claims from Novartis, which had sought to protect its original product, Lutathera, from competition.

This development not only opens the door for increased market competition but also signals a shift in the regulatory landscape for radioligand therapies. With the FDA’s endorsement, Curium is poised to capture a share of the growing market for targeted radioligand treatments, which have shown promise in treating neuroendocrine tumors. The implications of this approval extend beyond Curium, as it may encourage other companies to pursue similar pathways for developing generic alternatives, potentially reducing costs and improving patient access to these innovative therapies.